Corcept Therapeutics (CORT) Misses Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $117.90 +0.34%
Revenue Growth %: +56.0%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +56.0%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.06), $0.09 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $25.53 million.
GUIDANCE:
Corcept Therapeutics sees FY2017 revenue of $125-135 million, versus the consensus of $124 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Corcept names Justin Gunn president of endocrinology division
- Espey Manufacturing (ESP) Tops Q4 EPS by 24c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
